Olema Pharmaceuticals Inc
NASDAQ:OLMA
Olema Pharmaceuticals Inc
NASDAQ:OLMA
Price:
10.9 USD
2.16%
Market Closed
Updated:
May 7, 2024
Section:
Relative Value
There is not enough data to reliably calculate the relative value of OLMA.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
OLMA
Relative Value
Base Case
Not Available
Valuation Multiples
Multiples Across Competitors
OLMA Competitors Multiples
Olema Pharmaceuticals Inc Competitors
Olema Pharmaceuticals Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Olema Pharmaceuticals Inc
NASDAQ:OLMA
|
599.4m USD | 0 | -6.2 | -3.2 | -3.2 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
285.6B USD | 5.3 | 59.3 | 12.9 | 19.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
159.7B USD | 5.7 | 23.8 | 17.3 | 26 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
104.4B USD | 8 | 26.4 | 17.8 | 19.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.6B USD | 10.5 | 28.6 | 22.9 | 24 | |
| AU |
|
CSL Ltd
ASX:CSL
|
133.1B AUD | 6.2 | 35.7 | 21.6 | 26.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
80.3B USD | 3 | 165.8 | 6.6 | 8.7 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
45.9B USD | 6.8 | -9.7 | -10.5 | -8.9 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
32.1B USD | 3.3 | 27.5 | 14.1 | 17.6 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.2T KRW | 18 | 73.1 | 44.7 | 61.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
